Relmada Therapeutics Inc - Asset Resilience Ratio
Relmada Therapeutics Inc (RLMD) has an Asset Resilience Ratio of 95.25% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Relmada Therapeutics Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Relmada Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Relmada Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RLMD market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $224.19 Million | 95.25% |
| Total Liquid Assets | $224.19 Million | 95.25% |
Asset Resilience Insights
- Very High Liquidity: Relmada Therapeutics Inc maintains exceptional liquid asset reserves at 95.25% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Relmada Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Relmada Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for Relmada Therapeutics Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Relmada Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 95.22% | $89.51 Million | $94.00 Million | +5.62pp |
| 2024-12-31 | 89.60% | $41.05 Million | $45.82 Million | -4.95pp |
| 2023-12-31 | 94.55% | $92.23 Million | $97.55 Million | +1.07pp |
| 2022-12-31 | 93.47% | $142.93 Million | $152.91 Million | +18.49pp |
| 2021-12-31 | 74.99% | $167.47 Million | $223.33 Million | -21.97pp |
| 2020-12-31 | 96.96% | $114.60 Million | $118.19 Million | +28.52pp |
| 2019-12-31 | 68.44% | $80.16 Million | $117.14 Million | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more